Swedish drug discovery and development company Karo Bio AB announced on Thursday (14 Augusrt) that Wyeth (NYSE: WYE) and Karo Bio extended their atherosclerosis collaboration for an additional year until 31 August 2009. The primary objective of the extension is to identify and select development candidates for treatment of atherosclerosis and to further evaluate additional clinical possibilities by targeting LXR.
